Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Treating mantle cell lymphoma (Part 1)

Andre Goy and John Gribben • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma

Prof. John Gribben (Barts Cancer Institute, London, UK) interviews Prof Andre Goy (John Theurer Cancer Center, Hackensack, NJ) at the 2014 American Society of Hematology (ASH) Annual Meeting about current strategies for managing mantle cell lymphoma in the clinic. Topics include approaches to prolong progression-free survival; patient tolerability of aggressive approaches; treatment resistance; and novel biologic therapies.

More from Andre Goy

The latest developments in CAR-T and BiTE therapies for B-cell and mantle cell lymphoma
3:54
The latest developments in CAR-T and BiTE therapies for B-cell and mantle cell lymphoma
Andre Goy • 5 Jun 2022
Highlights in the field of lymphoma from ASCO 2022
2:02
Highlights in the field of lymphoma from ASCO 2022
Andre Goy • 5 Jun 2022
ASH 2014: Treating mantle cell lymphoma (Part 2)
7:38
ASH 2014: Treating mantle cell lymphoma (Part 2)
Andre Goy et al. • 5 Dec 2014
ASH 2014: Treating mantle cell lymphoma (Part 3)
2:21
ASH 2014: Treating mantle cell lymphoma (Part 3)
Andre Goy et al. • 5 Dec 2014

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals